Approval · Notice of Compliance 22758 · 2019
NUCALA: Notice of Compliance 22758
Issued October 8, 2019
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 22758
- Date
- October 8, 2019
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New formulation, additional manufacturing site and update to the product monograph
Products in this notice
Medicinal ingredients
- MEPOLIZUMAB 100 MG per SYR
- MEPOLIZUMAB 100 MG per ML